

# **Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/N101CCD0FCBEN.html>

Date: October 2018

Pages: 58

Price: US\$ 3,500.00 (Single User License)

ID: N101CCD0FCBEN

## **Abstracts**

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018

### **SUMMARY**

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimer's disease. Inhibition of neprilysin helps in treatment of Pain and hypertension.

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Acute Heart Failure, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Hypertension, Pain, Alzheimer's Disease, Cancer Pain, Diastolic Heart Failure, Keratoconjunctivitis Sicca (Dry Eye), Migraine, Neuropathic Pain (Neuralgia), Ocular Pain (Eye Pain), Post-Operative Pain, Resistant Hypertension, Systolic Heart Failure and Traumatic Pain.

The latest report Neprilysin - Pipeline Review, H2 2018, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)

The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics under

development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects

The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or

MME or EC 3.4.24.11)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Overview

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development

Novartis AG

Pharmaleads SA

Theravance Biopharma Inc

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles

(sacubitril + valsartan) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHW-090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-265 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-37 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Neprilysin for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STR-324 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-0714 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Dormant Products

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Discontinued Products

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Product Development Milestones

Featured News & Press Releases

Aug 25, 2018: Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode

May 28, 2018: Novartis International: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto

Apr 25, 2018: Real-world Data Show that Entresto Lowered Healthcare Costs in

## Patients with Heart Failure with Reduced Ejection Fraction

Apr 19, 2018: Pharmaleads to Present Data on PL37 at BioTrinity 2018 in London

Apr 19, 2018: Pharmaleads to Present Data on PL265 at BioTrinity 2018 in London

Apr 16, 2018: Novartis Announces new analysis demonstrating Entresto Helped Preserve Kidney Function in Patients with Chronic Heart Failure, Especially those with Diabetes

Apr 04, 2018: Novartis announces JAMA Cardiology Publication of Data Showing Entresto Improves Physical and Social Activity in HFrEF Patients Versus Enalapril

Mar 13, 2018: First subject enrolled in Phase I clinical trial of its non-opioid analgesic STR-324

Nov 12, 2017: New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure

Sep 19, 2017: New analysis shows Entresto improved physical and social activity in patients with HFrEF

Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain

May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting

May 09, 2017: Novartis heart failure treatment Entresto (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan

May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore

Mar 23, 2017: Novartis Pharmaceuticals Canada Announces Entresto now covered in Quebec

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd.1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Pharmaleads SA, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018

Discontinued Products, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Novartis AG

Pharmaleads SA

Theravance Biopharma Inc

## I would like to order

Product name: Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/N101CCD0FCBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N101CCD0FCBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970